Trial abstract · §3
EXENATIDE-GE-PD — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in the Movement Disorder Society Unified Parkinson’s Disease Rating Scale part 3 in the practically defined off-medication state | No significant difference from placebo. The Institute records this as a negative result of a widely publicised earlier phase 2 signal | Moderate |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Exenatide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 44.0 | 18.0 | AMIGO pooled (immediate release) |
| Vomiting | 13.0 | 4.0 | AMIGO pooled |
| Diarrhoea | 13.0 | 6.0 | AMIGO pooled |
| Injection-site nodule | — | — | A characteristic finding with the microsphere extended-release product, reported in up to 17 % and generally resolving over weeks to months |
| Acute pancreatitis | 0.2 | 0.1 | EXSCEL |
| Antibody formation | — | — | Higher than for human-sequence analogues, reflecting the non-human origin; high-titre antibodies attenuate efficacy in a minority |
| Discontinuation for adverse events | 8.0 | 3.0 | AMIGO pooled |
Compound Evidence Institute · CEI-TR-0088/3 · https://compoundevidence.com/trials/exenatide-ge-pd/results/ · retrieved 30 July 2026